Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease.

van Maurik IS, Visser LN, Pel-Littel RE, van Buchem MM, Zwan MD, Kunneman M, Pelkmans W, Bouwman FH, Minkman M, Schoonenboom N, Scheltens P, Smets EM, van der Flier WM.

JMIR Form Res. 2019 Jul 8;3(3):e13417. doi: 10.2196/13417.

2.

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease.

Babapour Mofrad R, Schoonenboom NSM, Tijms BM, Scheltens P, Visser PJ, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2018 Nov 12;11:1-9. doi: 10.1016/j.dadm.2018.10.004. eCollection 2019 Dec.

3.

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.

Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, Boelaarts L, Claus JJ, Korf ESC, van Marum RJ, Roks G, Schoonenboom N, Verwey N, Zwan MD, Wahl S, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2018 Sep 12;10:563-572. doi: 10.1016/j.dadm.2018.08.006. eCollection 2018.

4.

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility.

Jutten RJ, Harrison J, Lee Meeuw Kjoe PR, Opmeer EM, Schoonenboom NSM, de Jong FJ, Ritchie CW, Scheltens P, Sikkes SAM.

Alzheimers Dement (Amst). 2017 Dec 27;10:153-160. doi: 10.1016/j.dadm.2017.12.002. eCollection 2018.

5.

Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project.

Kunneman M, Pel-Littel R, Bouwman FH, Gillissen F, Schoonenboom NSM, Claus JJ, van der Flier WM, Smets EMA.

Alzheimers Dement (N Y). 2017 May 10;3(3):314-322. doi: 10.1016/j.trci.2017.04.002. eCollection 2017 Sep.

6.

Clinicians' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project.

Kunneman M, Smets EMA, Bouwman FH, Schoonenboom NSM, Zwan MD, Pel-Littel R, van der Flier WM.

Alzheimers Dement (N Y). 2017 May 10;3(3):305-313. doi: 10.1016/j.trci.2017.03.009. eCollection 2017 Sep.

7.

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design.

de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, Biessels GJ, Minkman M, Pel R, Schoonenboom NS, Smets EM, Wattjes MP, Barkhof F, Stephens A, van Lier EJ, Batrla-Utermann R, Scheltens P, Teunissen CE, van Berckel BN, van der Flier WM.

Alzheimers Dement (Amst). 2017 Jan 23;6:143-151. doi: 10.1016/j.dadm.2017.01.003. eCollection 2017.

8.

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.

Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM.

Neurology. 2012 Jan 3;78(1):47-54. doi: 10.1212/WNL.0b013e31823ed0f0. Epub 2011 Dec 14.

PMID:
22170879
9.

Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study.

van Duinkerken E, Klein M, Schoonenboom NS, Hoogma RP, Moll AC, Snoek FJ, Stam CJ, Diamant M.

Diabetes. 2009 Oct;58(10):2335-43. doi: 10.2337/db09-0425. Epub 2009 Jul 7.

10.

CSF biomarker levels in early and late onset Alzheimer's disease.

Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM.

Neurobiol Aging. 2009 Dec;30(12):1895-901. doi: 10.1016/j.neurobiolaging.2008.02.007. Epub 2008 Apr 9.

PMID:
18403055
11.

Inflammatory markers in AD and MCI patients with different biomarker profiles.

Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NS, Hack CE, Blankenstein MA, Jonker C.

Neurobiol Aging. 2009 Nov;30(11):1885-9. doi: 10.1016/j.neurobiolaging.2008.01.014. Epub 2008 Apr 18.

PMID:
18378357
12.

Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI.

Ewers M, Buerger K, Teipel SJ, Scheltens P, Schröder J, Zinkowski RP, Bouwman FH, Schönknecht P, Schoonenboom NS, Andreasen N, Wallin A, DeBernardis JF, Kerkman DJ, Heindl B, Blennow K, Hampel H.

Neurology. 2007 Dec 11;69(24):2205-12.

PMID:
18071141
13.

Longitudinal changes of CSF biomarkers in memory clinic patients.

Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Rijmen F, Blankenstein MA, Scheltens P.

Neurology. 2007 Sep 4;69(10):1006-11.

PMID:
17785669
14.

CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls.

Pijnenburg YA, Janssen JC, Schoonenboom NS, Petzold A, Mulder C, Stigbrand T, Norgren N, Heijst H, Hack CE, Scheltens P, Teunissen CE.

Dement Geriatr Cogn Disord. 2007;23(4):225-30. Epub 2007 Feb 9.

PMID:
17290105
15.

CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.

Schoonenboom NS, van der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, Scheltens P.

Neurobiol Aging. 2008 May;29(5):669-75. Epub 2007 Jan 17.

PMID:
17208336
16.

Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders.

Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Scheltens P, Blankenstein MA.

Clin Chem. 2006 Aug;52(8):1604-6. No abstract available.

17.

Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.

Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E.

Arch Neurol. 2006 Apr;63(4):538-43.

PMID:
16606766
18.

Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration.

Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YA, Bresolin N, Scarpini E.

Neurology. 2006 Jan 10;66(1):146-7. No abstract available.

PMID:
16401871
19.

Cerebrospinal fluid tau levels in frontotemporal dementia.

Verbeek MM, Pijnenburg YA, Schoonenboom NS, Kremer BP, Scheltens P.

Ann Neurol. 2005 Oct;58(4):656-7; author reply 657. No abstract available.

PMID:
16178027
20.

The transmethylation cycle in the brain of Alzheimer patients.

Mulder C, Schoonenboom NS, Jansen EE, Verhoeven NM, van Kamp GJ, Jakobs C, Scheltens P.

Neurosci Lett. 2005 Sep 30;386(2):69-71.

PMID:
16040194
21.

Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, Mehta PD.

Ann Neurol. 2005 Jul;58(1):139-42.

PMID:
15984010
22.

Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid.

Schoonenboom NS, Mulder C, Vanderstichele H, Pijnenburg YA, Van Kamp GJ, Scheltens P, Mehta PD, Blankenstein MA.

Clin Chem. 2005 Jun;51(6):1057-60. Epub 2005 Apr 21. No abstract available.

23.

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA.

Clin Chem. 2005 Jan;51(1):189-95. Epub 2004 Nov 11.

24.

CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration.

Pijnenburg YA, Schoonenboom NS, Rosso SM, Mulder C, Van Kamp GJ, Van Swieten JC, Scheltens P.

Neurology. 2004 May 11;62(9):1649. No abstract available.

PMID:
15136709
25.

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.

Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P.

Neurology. 2004 May 11;62(9):1580-4.

PMID:
15136685
26.

Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations.

Rosso SM, van Herpen E, Pijnenburg YA, Schoonenboom NS, Scheltens P, Heutink P, van Swieten JC.

Arch Neurol. 2003 Sep;60(9):1209-13.

PMID:
12975285
27.

Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients.

Galimberti D, Schoonenboom N, Scarpini E, Scheltens P; Dutch-Italian Alzheimer Research Group.

Ann Neurol. 2003 Apr;53(4):547-8. No abstract available.

PMID:
12666129
28.

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

Pijnenburg YA, Schoonenboom NS, Scheltens P.

Neurology. 2003 Jan 28;60(2):353-4; author reply 353-4. No abstract available.

PMID:
12552068
29.

Activation of the contact system of coagulation does not contribute to the hemostatic imbalance in hypertriglyceridemia.

Minnema MC, Wittekoek ME, Schoonenboom N, Kastelein JJ, Hack CE, ten Cate H.

Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2548-53.

PMID:
10521386

Supplemental Content

Loading ...
Support Center